体重指数与营养状态对头颈癌免疫治疗反应的影响
该队列研究利用美国Flatiron Health数据库2014至2024年数据,纳入1108例接受免疫治疗的晚期头颈鳞癌患者,评估基线BMI、治疗前BMI变化及预后营养指数(PNI)与无进展生存期(PFS)的关联。结果显示治疗前BMI下降及低PNI与更差PFS独立相关,而基线BMI无独立关联。
要点
- 治疗前BMI下降≥2%与更差PFS相关,需关注体重动态变化。
- 低PNI(<45)与更短PFS独立相关,提示免疫营养状态影响预后。
- 基线BMI分类与PFS无独立关联,静态指标预后价值有限。
核心结论
- 在晚期头颈鳞癌免疫治疗患者中,治疗前BMI下降和低PNI与PFS独立相关,而基线BMI无独立关联。
- 动态营养与免疫状态指标比静态指标提供更有意义的预后信息。
研究设计与样本
- 多机构回顾性队列研究,使用美国Flatiron Health数据库2014年1月至2024年1月去标识电子健康记录,随访3000天。
- 纳入1108例接受免疫治疗的晚期头颈鳞癌患者,平均年龄66.2岁(SD 10.2),女性236例(21.3%),男性872例(78.7%)。
主要发现
- 214例(79%)存在治疗前BMI下降≥2%。
- BMI下降与更差PFS相关(HR 1.17;95%CI 1.02-1.35),中位PFS为271天(IQR 121-603)对415天。
- 471例有实验室数据者中320例(67.9%)PNI低,低PNI与更短PFS相关(校正HR 1.58;95%CI 1.39-1.79),中位PFS为213天(IQR 98-445)对566天(IQR 307-1094)。
- 基线BMI分类与PFS无独立关联。
关键数值与推荐
- BMI下降定义:治疗前下降≥2%对比稳定。
- PNI低定义:<45对比正常≥45。
临床怎么用
- 治疗前应评估体重动态变化和PNI,识别营养风险高的患者。
- 营养优化可能作为改善免疫治疗结局的可干预因素。
局限性
- 回顾性队列设计,使用电子健康记录数据,可能存在混杂和缺失。
- PNI分析仅限471例有实验室数据的患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Malnutrition, common in patients with head and neck squamous cell carcinoma (HNSCC), may impair the effectiveness of immunotherapy. Understanding whether nutritional status affects outcomes can emphasize the importance of pretreatment nutritional optimization. OBJECTIVE: To evaluate the associations of body mass index (BMI), pretreatment BMI change, and prognostic nutritional index (PNI) with progression-free survival (PFS) in patients with advanced HNSCC treated with immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: Cohort study using deidentified electronic health records from the Flatiron Health database between January 2014 to January 2024, with follow-up of 3000 days in multiple cancer institutions across the US. Patients were from community and academic practices in the US, diagnosed with all types of advanced head and neck cancer who received immunotherapy (nivolumab, pembrolizumab, cemiplimab, durvalumab, atezolizumab, avelumab, or ipilimumab) between January 2014 and January 2024. Exclusion criteria included age younger than 18 years, patients without a diagnosis of squamous cell carcinoma, missing stage information, missing treatment information (eg, a gap in documented care of ≥90 days or more), and incomplete data needed to calculate BMI or PNI prior to initiation of therapy. EXPOSURES: Baseline BMI, pretreatment BMI change (≥2% decrease vs stable), and PNI (low <45 vs normal ≥45). MAIN OUTCOMES AND MEASURES: PFS following treatment with immunotherapy. RESULTS: Among 1108 patients (mean [SD] age, 66.2 [10.2] years; 236 [21.3%] female; 872 [78.7%] male), 214 (79%) experienced 2% or more pretreatment BMI loss. BMI loss was associated with worse PFS (hazard ratio, 1.17; 95% CI, 1.02-1.35); median PFS was 271 (IQR, 121-603) days with loss vs 415 days with stable BMI. In the 471 patients with laboratory data, 320 (67.9%) had a low PNI. Low PNI was associated with shorter PFS (adjusted hazard ratio, 1.58; 95% CI, 1.39-1.79); median PFS was 213 (IQR, 98-445) days for low vs 566 (IQR, 307-1094) days for patients with a normal PNI. Baseline BMI category was not independently associated with PFS. CONCLUSIONS AND RELEVANCE: In this large, nationally representative cohort of patients with advanced head and neck squamous cell carcinoma treated with immunotherapy, pretreatment BMI loss and low PNI were independently associated with PFS, while baseline BMI was not. These findings suggest that dynamic measures of nutrition and immune status provide more meaningful prognostic information than static measures. Nutritional optimization may represent a modifiable factor to improve outcomes in patients receiving immunotherapy for advanced head and neck squamous cell carcinoma.
引用
- Gabra L, Nitsch A, Wang Y, et al. Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41926098. doi:10.1001/jamaoto.2026.0166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。